F

FORESTIERI V.

Last name: FORESTIERI V.

2021 (v1)

Publication

Metadata-only

Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': (ESMO Open (2021) 6(2), (S2059702921000089), (10.1016/j.esmoop.2021.100054))

De Angelis C. Bruzzese D. Bernardo A.

The authors regret that at the time the article was published the following two authors were missing from the author list: R. Caputo and D. Cianniello. Both authors affiliation is the Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy. The updated author list is as follows: C. De Angelis, D. Bruzzese, A....

Uploaded on: February 14, 2024
2019 (v1)

Publication

Metadata-only

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial

Perrone F. De Laurentiis M. De Placido S.

Aim: The aim of the study is to analyse whether letrozole (L) and zoledronic acid plus L (ZL) are more effective than tamoxifen (T) as adjuvant endocrine treatment of premenopausal patients with breast cancer with hormone receptor–positive (HR+) tumours. Patients and methods: In a phase 3 trial, 1065 premenopausal patients with HR + early...

Uploaded on: March 27, 2023